Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eltrombopag + prednisone + romiplostim
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of two thrombopoietin receptor agonists (eltrombopag and romiplostim) and a corticosteroid (prednisone). This combination has been used successfully in cases of severe thrombocytopenia, particularly in Evans syndrome and immune thrombocytopenic purpura (ITP) that have been refractory to standard treatments. The medications work through complementary mechanisms: eltrombopag binds to the transmembrane domain of the thrombopoietin receptor, romiplostim binds directly to the thrombopoietin binding site, and prednisone reduces autoimmune destruction of platelets.
02
Targets
GR (Glucocorticoid receptor)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on eltrombopag + prednisone + romiplostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eltrombopag + prednisone + romiplostim.